Jack Schalken was trained as Biochemist at the Radboud University Nijmegen, Nijmegen, GLD, The Netherlands, where he also obtained his Ph.D. degree (1987). He did his Postdoc with Dr. John T Isaacs at Johns Hopkins Hospital (Baltimore, Md, USA). Since then Schalken serves as the Director of urological research at the Radboud University Medical Center and his lab is housed in the Nijmegen Center for Molecular Life Sciences (www.ncmls.ru.nl), Nijmegen, GLD, The Netherlands, a state-of-the-art research facility for molecular and cell biology. In 1996 Dr. Schalken was appointed as Full Professor of experimental oncology at the University of Utrecht, Utrecht, UT, The Netherlands. Since 2001 he works as a Professor of experimental urology at the Radboud University Nijmegen. He is the author or coauthor of more than 310 peer-reviewed publications and 75 chapters. His research focuses on the molecular and cellular basis of GU cancer, particularly prostate cancer. Specific themes include unravelling the mechanism of GU cancer invasion/cadherin switching; molecular diagnostics of prostate cancer, PCA3; cancer stem/initiating cells; and targeted therapy in GU cancer. Professor Schalken’s team discovered the recently introduced PrCa specific biomarker.
Biography Updated on 8 January 2013